These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527 [TBL] [Abstract][Full Text] [Related]
44. Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Kaynak D; Kiziltan G; Kaynak H; Benbir G; Uysal O Eur J Neurol; 2005 Mar; 12(3):199-207. PubMed ID: 15693809 [TBL] [Abstract][Full Text] [Related]
45. Analysis of nocturnal hypokinesia and sleep quality in Parkinson's disease. Xue F; Wang FY; Mao CJ; Guo SP; Chen J; Li J; Wang QJ; Bei HZ; Yu Q; Liu CF J Clin Neurosci; 2018 Aug; 54():96-101. PubMed ID: 29908717 [TBL] [Abstract][Full Text] [Related]
46. Perception of sleep: subjective versus objective sleep parameters in patients with Parkinson's disease in comparison with healthy elderly controls. Sleep perception in Parkinson's disease and controls. Happe S; Klösch G; Lorenzo J; Kunz D; Penzel T; Röschke J; Himanen SL; Gruber G; Zeitlhofer J J Neurol; 2005 Aug; 252(8):936-43. PubMed ID: 15765195 [TBL] [Abstract][Full Text] [Related]
47. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269 [TBL] [Abstract][Full Text] [Related]
48. Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease. Mirelman A; Hillel I; Rochester L; Del Din S; Bloem BR; Avanzino L; Nieuwboer A; Maidan I; Herman T; Thaler A; Gurevich T; Kestenbaum M; Orr-Urtreger A; Brys M; Cedarbaum JM; Giladi N; Hausdorff JM Mov Disord; 2020 Jun; 35(6):959-968. PubMed ID: 32080891 [TBL] [Abstract][Full Text] [Related]
49. Quantitative assessment of parkinsonian patients by continuous wrist activity monitoring. Van Hilten JJ; Hoogland G; van der Velde EA; van Dijk JG; Kerkhof GA; Roos RA Clin Neuropharmacol; 1993 Feb; 16(1):36-45. PubMed ID: 8422656 [TBL] [Abstract][Full Text] [Related]
50. Evaluating the Efficacy of Nocturnal Continuous Subcutaneous Apomorphine Infusion in Sleep Disorders in Advanced Parkinson's Disease: The APO-NIGHT Study. Fernández-Pajarín G; Sesar Á; Ares B; Castro A J Parkinsons Dis; 2016 Oct; 6(4):787-792. PubMed ID: 27662329 [TBL] [Abstract][Full Text] [Related]
51. Does levodopa slow or hasten the rate of progression of Parkinson's disease? Fahn S; J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436 [TBL] [Abstract][Full Text] [Related]
52. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease. Herz DM; Siebner HR; Hulme OJ; Florin E; Christensen MS; Timmermann L Neuroimage; 2014 Apr; 90():15-23. PubMed ID: 24269570 [TBL] [Abstract][Full Text] [Related]
53. Sleep quality is associated with the severity of clinical symptoms in Parkinson's disease. Junho BT; Kummer A; Cardoso FE; Teixeira AL; Rocha NP Acta Neurol Belg; 2018 Mar; 118(1):85-91. PubMed ID: 29210000 [TBL] [Abstract][Full Text] [Related]
54. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. Högl BE; Gómez-Arévalo G; García S; Scipioni O; Rubio M; Blanco M; Gershanik OS Neurology; 1998 May; 50(5):1332-9. PubMed ID: 9595983 [TBL] [Abstract][Full Text] [Related]
55. Lifecorder: a new device for the long-term monitoring of motor activities for Parkinson's disease. Saito N; Yamamoto T; Sugiura Y; Shimizu S; Shimizu M Intern Med; 2004 Aug; 43(8):685-92. PubMed ID: 15468966 [TBL] [Abstract][Full Text] [Related]
56. Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. A study with the WOQ-19 questionnaire. Pistacchi M; Gioulis M; Sanson F; Marsala SZ Neurol India; 2017; 65(6):1271-1279. PubMed ID: 29133700 [TBL] [Abstract][Full Text] [Related]
57. Daytime sleepiness and other sleep disorders in Parkinson's disease. Ondo WG; Dat Vuong K; Khan H; Atassi F; Kwak C; Jankovic J Neurology; 2001 Oct; 57(8):1392-6. PubMed ID: 11673578 [TBL] [Abstract][Full Text] [Related]
58. Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls. Louter M; Maetzler W; Prinzen J; van Lummel RC; Hobert M; Arends JB; Bloem BR; Streffer J; Berg D; Overeem S; Liepelt-Scarfone I J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):32-7. PubMed ID: 24777169 [TBL] [Abstract][Full Text] [Related]
59. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Parkinson Study Group CALM Cohort Investigators Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655 [TBL] [Abstract][Full Text] [Related]
60. [Effects of the dopamine agonist mirapex (pramipexole) therapy on sleep disorders in Parkinson's disease]. Nodel' MR Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):42-7. PubMed ID: 20517225 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]